Interleukin-13 IgGFc fusion protein

Drug Profile

Interleukin-13 IgGFc fusion protein

Alternative Names: IL-13 antagonist - Wyeth; IL-13-α-2-IgGFc fusion protein; Interleukin-13 antagonist - Wyeth; sIL-13R-α-2-Fc

Latest Information Update: 03 Oct 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Class Antiasthmatics
  • Mechanism of Action Interleukin 13 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Allergic asthma; Hepatic fibrosis

Most Recent Events

  • 17 Feb 2006 No development reported - Preclinical for Allergic asthma in USA (unspecified route)
  • 17 Feb 2006 No development reported - Preclinical for Hepatic fibrosis in USA (unspecified route)
  • 29 Jan 2003 Genetics Institute is now called Wyeth
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top